Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness

This article was originally published in The Tan Sheet

Executive Summary

June launch of Clearblue digital pregancy test to be followed by digital ovulation test next year, CEO Ron Zwanziger says at UBS Global Life Sciences Conference Sept. 23 (1"The Tan Sheet" Aug. 4, 2003, p. 9). Fifteen-second ad spots for Clearblue digital pregnancy test began airing on network TV Sept. 15, are slated to break on cable TV in October, he states. Tagline "if only everything in life were this clear," created by Christian, Baum and Bond (New York), targets women ages 25-36. "It is too early to say how sales [of the product] are doing, but we have seen encouraging early results," Zwanziger notes, predicting Inverness Medical Innovations revenues will reach $275 mil. in FY 2003...

You may also be interested in...



Inverness Expands Home Pregnancy Market Share With Fact Plus Acquisition

Inverness Medical Innovations will immediately take over distribution of Abbott Labs' Fact plus OTC home pregnancy tests after acquiring the line along with several professional test kit products from the firm in a $92.5 mil. deal

Inverness Building Consumer Product Sales, Has High Hopes For Clearblue

Consumer products contributed roughly three-quarters of Inverness Medical Innovations' $65.7 mil. second quarter net revenues, the firm reported in a July 31 earnings call

Bayer Confident CureVac COVID Pact Will Be A Success

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel